These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16866917)

  • 21. The link between altered cholesterol metabolism and Alzheimer's disease.
    Gamba P; Testa G; Sottero B; Gargiulo S; Poli G; Leonarduzzi G
    Ann N Y Acad Sci; 2012 Jul; 1259():54-64. PubMed ID: 22758637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol-dependent modulation of tau phosphorylation in cultured neurons.
    Fan QW; Yu W; Senda T; Yanagisawa K; Michikawa M
    J Neurochem; 2001 Jan; 76(2):391-400. PubMed ID: 11208902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain cholesterol, statins and Alzheimer's Disease.
    Kirsch C; Eckert GP; Koudinov AR; Müller WE
    Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S113-9. PubMed ID: 14574624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoprenoids and Alzheimer's disease: a complex relationship.
    Cole SL; Vassar R
    Neurobiol Dis; 2006 May; 22(2):209-22. PubMed ID: 16406223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology.
    Pappolla MA
    Neurology; 2008 Dec; 71(24):2020; author reply 2020-1. PubMed ID: 19086266
    [No Abstract]   [Full Text] [Related]  

  • 26. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
    Kurata T; Miyazaki K; Kozuki M; Panin VL; Morimoto N; Ohta Y; Nagai M; Ikeda Y; Matsuura T; Abe K
    Brain Res; 2011 Jan; 1371():161-70. PubMed ID: 21112317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain.
    Distl R; Treiber-Held S; Albert F; Meske V; Harzer K; Ohm TG
    J Pathol; 2003 May; 200(1):104-11. PubMed ID: 12692848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application.
    Jiao X; Ashtari N; Rahimi-Balaei M; Chen QM; Badbezanchi I; Shojaei S; Marzban A; Mirzaei N; Chung S; Guan T; Li J; Vriend J; Mehr SE; Kong J; Marzban H
    Curr Mol Pharmacol; 2017; 10(2):115-140. PubMed ID: 26758948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conserved statin-mediated activation of the p38-MAPK pathway protects Caenorhabditis elegans from the cholesterol-independent effects of statins.
    Goncalves IL; Tal S; Barki-Harrington L; Sapir A
    Mol Metab; 2020 Sep; 39():101003. PubMed ID: 32339771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
    Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
    Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration.
    Pac-Soo C; Lloyd DG; Vizcaychipi MP; Ma D
    J Alzheimers Dis; 2011; 27(1):1-10. PubMed ID: 21734347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cholesterol metabolic disorders and Alzheimer's disease].
    Hao JW; Li L
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):64-6. PubMed ID: 15881350
    [No Abstract]   [Full Text] [Related]  

  • 33. Cholesterol and Alzheimer's disease--is there a relation?
    Sjögren M; Mielke M; Gustafson D; Zandi P; Skoog I
    Mech Ageing Dev; 2006 Feb; 127(2):138-47. PubMed ID: 16332384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
    Meske V; Albert F; Richter D; Schwarze J; Ohm TG
    Eur J Neurosci; 2003 Jan; 17(1):93-102. PubMed ID: 12534972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth inhibition of Candida species and Aspergillus fumigatus by statins.
    Macreadie IG; Johnson G; Schlosser T; Macreadie PI
    FEMS Microbiol Lett; 2006 Sep; 262(1):9-13. PubMed ID: 16907733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease.
    Martins IJ; Berger T; Sharman MJ; Verdile G; Fuller SJ; Martins RN
    J Neurochem; 2009 Dec; 111(6):1275-308. PubMed ID: 20050287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
    Sala SG; Muñoz U; Bartolomé F; Bermejo F; Martín-Requero A
    J Pharmacol Exp Ther; 2008 Jan; 324(1):352-9. PubMed ID: 17928568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relation between cholesterol levels, statins and Alzheimer's disease in the human population.
    Austen B; Christodoulou G; Terry JE
    J Nutr Health Aging; 2002; 6(6):377-82. PubMed ID: 12459888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of autophagy mechanism of statins in the potential therapy of Alzheimer's disease.
    Liu L; Dai WZ; Zhu XC; Ma T
    J Integr Neurosci; 2022 Mar; 21(2):46. PubMed ID: 35364634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.